logo

Idera Pharmaceuticals, Inc. (IDRA)



Trade IDRA now with
  Date
  Headline
1/5/2018 7:03:11 AM Idera Pharma Provides 2018 Update And Outlook
11/29/2017 7:33:00 AM FDA Grants Fast Track Designation For Idera’ IMO-2125 In Combination With Ipilimumab
11/15/2017 5:33:12 PM Wedbush Is Lowering Idera Pharmaceuticals, Inc. (IDRA) FY18 Rev. Estimate To 0.0 M From 0.8 M
11/15/2017 5:33:02 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q4 18 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:32:52 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q3 18 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:32:44 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q2 18 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:32:18 PM Wedbush Is Lowering Idera Pharmaceuticals, Inc. (IDRA) Q1 18 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:31:53 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) FY17 Rev. Estimate To 0.7 M From 1.0 M
11/15/2017 5:31:39 PM Wedbush Is Lowering Idera Pharmaceuticals, Inc. (IDRA) Q4 17 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:31:05 PM Wedbush Is Increasing Idera Pharmaceuticals, Inc. (IDRA) FY18 Estimate To -0.37 From -0.47
11/15/2017 5:30:27 PM Wedbush Is Raising Idera Pharmaceuticals, Inc. (IDRA) Q4 18 Estimate To -0.10 From -0.13
11/15/2017 5:30:10 PM Wedbush Is Raising Idera Pharmaceuticals, Inc. (IDRA) Q3 18 Estimate To -0.09 From -0.12
11/15/2017 5:29:52 PM Wedbush Is Increasing Idera Pharmaceuticals, Inc. (IDRA) Q2 18 Estimate To -0.09 From -0.11
11/15/2017 5:29:32 PM Wedbush Is Raising Idera Pharmaceuticals, Inc. (IDRA) Q1 18 Estimate To -0.09 From -0.11
11/15/2017 5:29:19 PM Wedbush Is Raising Idera Pharmaceuticals, Inc. (IDRA) FY17 Estimate To -0.42 From -0.47
11/15/2017 5:28:58 PM Wedbush Is Increasing Idera Pharmaceuticals, Inc. (IDRA) Q4 17 Estimate To -0.08 From -0.12
11/9/2017 8:18:14 AM Idera Presents Positive Translational And Clinical Data Update From Ongoing IMO-2125 Development Program
10/26/2017 7:15:41 AM Idera Pharma Announces Pricing Of Public Offering Of Common Stock
9/10/2017 7:17:49 AM Idera Presents Positive Phase 1 Data For Intratumoral IMO-2125 In Combination With Ipilimumab